Victoria Bîrluţiu, Mirela Mitrea
Clinica Boli Infecţioase Sibiu
Abstract
Kaposi sarcoma, a vascular proliferate malignant disease (a malignant, multi-focal systemic disease that originates from the vascular endothelium), associated with the HIV infection is widely witnessed in drug users that administrate it by intravenous injection, in women, or hemophiliacs. The drop of CD4 cells below 200/mm3 may determine the spreading of the Kaposis sarcoma to skin, but also to colon, lungs, genital organs, lymphatic system. The treatment for the common injuries includes chemotherapy, radiotherapy, surgical treatment, local administration of cytostatics (vinblastina), retinoids –like Alitretinoin gel. More extensive forms of the disease require a general cytostatic treatment (such as bleomycin, etoposide, vinblastine, vincristine), liposomal forms of anthracyclines (such as pegylated liposomal doxorubicin or daunorubicin), paclitaxel, Imatinib, interferon, interferon in association with cytostatics, isotretinoin, cytokine inhibitors, HCG (human chorionic gonadotropin). We hereby present the case of M.T., a 41 years old male patient, infected with HIV since 2002, with no HAART therapy, presenting antecedents of pulmonary tuberculosis, gonorrhea, malignant syphilis (lues maligna), who developed Kaposi sarcoma disease affecting the skin, oral mucus, lung, genital organs, with values of CD4 ranging over 200/mm3, with a good clinical evolution after initiating the HAART therapy, associated with the systemic chemotherapy.